David H Henry

List of Publications by Year
in descending order

82 papers	2,058 citations	361413 20 h-index	243625 44 g-index
82 all docs	82 docs citations	82 times ranked	2654 citing authors

#	Article	IF	Citations
1	Roxadustat for the treatment of anemia in patients with <scp>lowerâ€risk</scp> myelodysplastic syndrome: Openâ€label, doseâ€selection, leadâ€in stage of a phase 3 study. American Journal of Hematology, 2022, 97, 174-184.	4.1	35
2	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. Oncologist, 2022, 27, 623-e624.	3.7	2
3	Abstract P1-20-02: A machine learning approach to identify risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from breast cancer. Cancer Research, 2022, 82, P1-20-02-P1-20-02.	0.9	0
4	Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clinical Cancer Research, 2022, , .	7.0	0
5	Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach. Journal of Bone Oncology, 2022, 34, 100423.	2.4	9
6	Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Supportive Care in Cancer, 2022, , 1.	2.2	0
7	Open-label, phase 2 study of roxadustat for treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.. Journal of Clinical Oncology, 2022, 40, 12085-12085.	1.6	1
8	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica, 2021, 106, 730-735.	3.5	8
9	Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. American Journal of Hematology, 2021, 96, 727-734.	4.1	14
10	Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach.. Journal of Clinical Oncology, 2021, 39, 1567-1567.	1.6	0
11	A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).. Journal of Clinical Oncology, 2021, 39, TPS3614-TPS3614.	1.6	3
12	Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, p<scp>laceboâ€controlled</scp> study (<scp>IRON</scp>â€<scp>CLAD</scp>). American Journal of Hematology, 2021, 96, 1639-1646.	4.1	8
13	A retrospective analysis of venous thromboembolism trends in chemotherapyâ€induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration. EJHaem, 2020, 1, 35-43.	1.0	1
14	Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Current Medical Research and Opinion, 2020, 36, 1519-1527.	1.9	0
15	Patterns of granulocyte colonyâ€“stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Supportive Care in Cancer, 2020, 28, 4413-4424.	2.2	20
16	Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels. Blood, 2020, 136, 29-30.	1.4	4
17	Highlights of BRCA genetic testing in prostate cancer from a real-world patient cohort in Australia.. Journal of Clinical Oncology, 2020, 38, e13574-e13574.	1.6	0
18	A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia.. Journal of Clinical Oncology, 2020, 38, e15515-e15515.	1.6	0

#	Article	IF	Citations
19	A prospective, multiâ€center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWONâ€IDA trial. American Journal of Hematology, 2019, 94, 1007-1014.	4.1	62
20	Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al.. International Journal of Clinical Pharmacy, 2019, 41, 619-620.	2.1	0
21	Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States. Current Medical Research and Opinion, 2019, 35, 375-381.	1.9	7
22	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. Blood, 2019, 134, 130-130.	1.4	5
23	Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB). Blood, 2019, 134, 843-843.	1.4	16
24	Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD). Blood, 2019, 134, 3535-3535.	1.4	3
25	A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent (ESA) administration.. Journal of Clinical Oncology, 2019, 37, e14685-e14685.	1.6	0
26	A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration. Blood, 2019, 134, 4944-4944.	1.4	0
27	Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma. Blood, 2019, 134, 2872-2872.	1.4	0
28	Safety and Preliminary Efficacy of Vorinostat WithÂR-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 180-190.e2.	0.4	11
29	Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. Aids, 2018, 32, 605-611.	2.2	24
30	Isolated hypoglossal nerve palsy as a presenting symptom of metastatic peripheral T-cell lymphoma â€“Ânot otherwise specified (PTCLâ€“NOS): a unique case & a review of the literature. International Journal of Hematologic Oncology, 2018, 7, IJH03.	1.6	4
31	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Advances, 2018, 2, 575-585.	5.2	7
32	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Advances, 2018, 2, 3618-3626.	5.2	9
33	Double the Trouble: Acute Coronary Syndrome and Ischemic Stroke in Polycythemia Vera. American Journal of Medicine, 2017, 130, e237-e240.	1.5	6
34	Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. Journal of Clinical Oncology, 2017, 35, 727-733.	1.6	64
35	Changes in the use of erythropoiesisâ€stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes. Pharmacoepidemiology and Drug Safety, 2017, 26, 1357-1366.	1.9	5
36	Management of anemia in patients with congestive heart failure. American Journal of Hematology, 2017, 92, 88-93.	4.1	43

#	Article	IF	Citations
37	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research, 2016, 22, 5713-5721.	7.0	37
38	A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The <scp>PROFOUND</scp> Trial. Pharmacotherapy, 2016, 36, 402-414.	2.6	48
39	Primary neuroendocrine tumour of the right ventricle presenting with heart failure and cyanosis. BMJ Case Reports, 2016, 2016, bcr2016214810.	0.5	4
40	AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. Blood, 2016, 128, 786-786.	1.4	2
41	An interview with David Henry: supportive oncology, anemia and cancer. International Journal of Hematologic Oncology, 2015, 4, 129-131.	1.6	0
42	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European Journal of Cancer, 2015, 51, 1812-1821.	2.8	106
43	Sarcoidosis, complete heart block, and warm autoimmune hemolytic anemia in a young woman. Journal of Community and Supportive Oncology, 2015, 13, 159-161.	0.1	4
44	Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies.. Journal of Clinical Oncology, 2015, 33, e22236-e22236.	1.6	0
45	Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer, 2014, 22, 679-687.	2.2	146
46	Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4762-8.	7.1	34
47	Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars. Seminars in Oncology, 2014, 41, S13-S20.	2.2	45
48	Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.. Journal of Clinical Oncology, 2014, 32, 11028-11028.	1.6	2
49	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. Journal of Clinical Oncology, 2014, 32, 9501-9501.	1.6	2
50	AIDS-defining cancers (ADC) and non-AIDS defining cancers (NADC) in HIV-infected individuals and degree of immunosuppression.. Journal of Clinical Oncology, 2014, 32, e22096-e22096.	1.6	0
51	Reply to Araki et al.. European Journal of Cancer, 2013, 49, 2266-2268.	2.8	1
52	Hypocalcemia in patients with metastatic bone disease receiving denosumab.. Journal of Clinical Oncology, 2013, 31, 9628-9628.	1.6	2
53	Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.. Journal of Clinical Oncology, 2013, 31, 9640-9640.	1.6	4
54	Readmission Rates Due To Venous Thromboembolism In Cancer Patients After Abdominopelvic Surgery. Blood, 2013, 122, 2940-2940.	1.4	0

#	Article	IF	Citations
55	Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2012, 7, 1823-1829.	1.1	281
56	Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Supportive Care in Cancer, 2012, 20, 2089-2096.	2.2	22
57	Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. American Journal of Hematology, 2012, 87, 308-310.	4.1	69
58	Assessing a prognostic model for predicting VTE occurrence in cancer patients.. Journal of Clinical Oncology, 2012, 30, 1577-1577.	1.6	3
59	Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.. Journal of Clinical Oncology, 2012, 30, 4030-4030.	1.6	17
60	Parenteral Iron Therapy in Cancer-Associated Anemia. Hematology American Society of Hematology Education Program, 2010, 2010, 351-356.	2.5	20
61	A Retrospective Study On the Efficacy of Relative Dose Intensities of Non-Hodgkin's Lymphoma Treatments: Response to Chemotherapy and Overall Survival.. Blood, 2009, 114, 1388-1388.	1.4	0
62	Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.. Supportive Care in Cancer, 2008, 16, 791-801.	2.2	303
63	Natural History of Anemia Associated with Interferon/Ribavirin Therapy for Patients with HIV/HCV Coinfection. AIDS Research and Human Retroviruses, 2007, 23, 1-9.	1.1	15
64	Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy. Oncologist, 2007, 12, 231-242.	3.7	250
65	Epoetin Alfa Treatment for Patients with Chemotherapy-Induced Anemia. Supportive Cancer Therapy, 2007, 4, 78-91.	0.3	2
66	Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies. Drugs, 2007, 67, 175-194.	10.9	8
67	Is Thromboembolism in Cancer Patients Treated with Erythropoietic Stimulating Agents Related to Thrombocytosis and Iron Restricted Erythropoiesis?.. Blood, 2007, 110, 1625-1625.	1.4	10
68	A Retrospective Chart Review of the Hematologic Consequences of Roux-en-y Gastric Bypass Surgery.. Blood, 2007, 110, 3772-3772.	1.4	0
69	Randomized, open-label comparison of epoetin alfa extended dosing (80â€‰000â€‰U Q2W) vs weekly dosing (40â€‰000â€‰U QW) in patients with chemotherapy-induced anemia. Current Medical Research and Opinion, 2006, 22, 1403-1413.	1.9	25
70	The Patientâ€™s Experience of Fatigue: A Cross-Sectional Study of Cancer Patients.. Blood, 2006, 108, 3356-3356.	1.4	1
71	Biochemical Markers of Iron Status Are of Limited Value in the Diagnosis of Iron Deficiency Associated with Anemia of Chronic Disease.. Blood, 2006, 108, 3746-3746.	1.4	11
72	Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).. Blood, 2006, 108, 3764-3764.	1.4	0

#	Article	IF	Citations
73	The role of intravenous iron in cancer-related anemia. Oncology, 2006, 20, 21-4.	0.5	7
74	Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opinion on Pharmacotherapy, 2005, 6, 295-310.	1.8	12
75	Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treatment Practice. Transfusion Alternatives in Transfusion Medicine, 2005, 6, 14-25.	0.2	2
76	Epoetin Alfa. Archives of Internal Medicine, 2004, 164, 262.	3.8	86
77	The Evolving Role of Epoetin Alfa in Cancer Therapy. Oncologist, 2004, 9, 97-107.	3.7	26
78	Epoetin Alfa for Treatment of Anemia in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1221-1227.	2.1	14
79	Intravenous Ferric Gluconate (FG) for Increasing Response to Epoetin (EPO) in Patients with Anemia of Cancer Chemotherapy - Results of a Multicenter, Randomized Trial.. Blood, 2004, 104, 3696-3696.	1.4	15
80	Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent. Oncology, 2002, 16, 9-12.	0.5	51
81	Case report of a normal hemoglobin at presentation of thrombotic thrombocytopenic purpura. American Journal of Hematology, 2001, 68, 302-303.	4.1	0
82	Costs of Epoetin in Patients with AIDS. Pharmacoeconomics, 1994, 5, 446-447.	3.3	0